Recent studies have revealed that activation of the Wnt/β‐catenin pathway contributes to adaptive drug resistance to BRAF inhibitors in CRC.[37] However, effective clinical strategies targeting the Wnt/β‐catenin pathway are currently unavailable probably due to the on‐target toxicity,[38] which prompts the exploration of clinical strategy based on other targets. This evidence concerns the gene BRAF and colorectal carcinoma.